USD 2.07
(-3.72%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 3.05 Million USD | -89.24% |
2022 | 28.46 Million USD | -21.7% |
2021 | 36.35 Million USD | 32.34% |
2020 | 27.46 Million USD | 581.23% |
2019 | 4.03 Million USD | -27.0% |
2018 | 5.52 Million USD | 193.62% |
2017 | 1.88 Million USD | 106.18% |
2016 | -30.44 Million USD | -38.38% |
2015 | -21.99 Million USD | -468.86% |
2014 | 5.96 Million USD | 49600.0% |
2013 | 12 Thousand USD | -25.0% |
2012 | 16 Thousand USD | -30.43% |
2011 | 23 Thousand USD | 0.0% |
2010 | - USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 Q2 | 990 Thousand USD | -50.18% |
2023 Q1 | 1.98 Million USD | -52.69% |
2023 FY | 3.06 Million USD | -89.24% |
2022 Q3 | 8.1 Million USD | -13.37% |
2022 Q1 | 10.2 Million USD | 272.74% |
2022 Q2 | 9.35 Million USD | -8.34% |
2022 FY | 28.46 Million USD | -21.7% |
2022 Q4 | 4.2 Million USD | -48.15% |
2021 Q2 | 10.91 Million USD | 5.72% |
2021 Q3 | 12.38 Million USD | 13.45% |
2021 Q4 | 2.73 Million USD | -77.89% |
2021 FY | 36.35 Million USD | 32.34% |
2021 Q1 | 10.32 Million USD | -4.51% |
2020 FY | 27.46 Million USD | 581.23% |
2020 Q1 | -659 Thousand USD | -182.17% |
2020 Q2 | 6.71 Million USD | 1118.36% |
2020 Q3 | 10.6 Million USD | 58.04% |
2020 Q4 | 10.8 Million USD | 1.91% |
2019 Q3 | 772 Thousand USD | -32.16% |
2019 Q1 | 1.32 Million USD | 70.32% |
2019 Q2 | 1.13 Million USD | -13.79% |
2019 FY | 4.03 Million USD | -27.0% |
2019 Q4 | 802 Thousand USD | 3.89% |
2018 FY | 5.52 Million USD | 193.62% |
2018 Q4 | 775 Thousand USD | -51.8% |
2018 Q3 | 1.6 Million USD | -1.05% |
2018 Q2 | 1.62 Million USD | 7.26% |
2018 Q1 | 1.51 Million USD | 40.02% |
2017 Q3 | 588 Thousand USD | 178.67% |
2017 Q4 | 1.08 Million USD | 84.01% |
2017 FY | 1.88 Million USD | 106.18% |
2017 Q2 | 211 Thousand USD | 0.0% |
2017 Q1 | - USD | 100.0% |
2016 FY | -30.44 Million USD | -38.38% |
2016 Q4 | -30.44 Million USD | 0.0% |
2016 Q3 | - USD | -100.0% |
2016 Q2 | 1000.00 USD | 0.0% |
2016 Q1 | - USD | 100.0% |
2015 Q1 | 1000.00 USD | 0.0% |
2015 FY | -21.99 Million USD | -468.86% |
2015 Q4 | -22 Million USD | -2200300.0% |
2015 Q3 | 1000.00 USD | 0.0% |
2015 Q2 | 1000.00 USD | 0.0% |
2014 FY | 5.96 Million USD | 49600.0% |
2014 Q4 | 1000.00 USD | -75.0% |
2014 Q2 | 4000.00 USD | -99.93% |
2014 Q1 | 5.95 Million USD | 595400.0% |
2014 Q3 | 4000.00 USD | 0.0% |
2013 FY | 12 Thousand USD | -25.0% |
2013 Q2 | 4000.00 USD | 0.0% |
2013 Q1 | 4000.00 USD | 0.0% |
2013 Q3 | 3000.00 USD | -25.0% |
2013 Q4 | 1000.00 USD | -66.67% |
2012 Q4 | 4000.00 USD | 33.33% |
2012 Q1 | 4000.00 USD | 33.33% |
2012 Q3 | 3000.00 USD | -40.0% |
2012 Q2 | 5000.00 USD | 25.0% |
2012 FY | 16 Thousand USD | -30.43% |
2011 FY | 23 Thousand USD | 0.0% |
2011 Q3 | 11 Thousand USD | 0.0% |
2011 Q4 | 3000.00 USD | -72.73% |
2010 FY | - USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Esperion Therapeutics, Inc. | 73.06 Million USD | 95.82% |
Theratechnologies Inc. | 62.12 Million USD | 95.084% |
Safety Shot Inc | -74.45 Thousand USD | 4201.929% |
Cosmos Health Inc. | 4.34 Million USD | 29.782% |
Cronos Group Inc. | 6.99 Million USD | 56.312% |
Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 99.308% |
Kala Pharmaceuticals, Inc. | -303 Thousand USD | 1107.978% |
Organogenesis Holdings Inc. | 309.79 Million USD | 99.014% |
Universe Pharmaceuticals INC | 10.07 Million USD | 69.694% |
ProPhase Labs, Inc. | 16.23 Million USD | 81.192% |
Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | 35.634% |
Dynavax Technologies Corporation | 182.11 Million USD | 98.323% |
Radius Health, Inc. | 307.71 Million USD | 99.007% |
China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -451.324% |
Alvotech | -69.42 Million USD | 104.399% |
Sunshine Biopharma, Inc. | 8.33 Million USD | 63.376% |
Alpha Teknova, Inc. | 10.29 Million USD | 70.336% |
Intra-Cellular Therapies, Inc. | 430.62 Million USD | 99.291% |
SCYNEXIS, Inc. | 124.51 Million USD | 97.547% |
Harrow Health, Inc. | 90.55 Million USD | 96.627% |
Biofrontera Inc. | 16.62 Million USD | 81.631% |
DURECT Corporation | 6.83 Million USD | 55.29% |
Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 99.417% |
ANI Pharmaceuticals, Inc. | 305.3 Million USD | 99.0% |
OptiNose, Inc. | 62.35 Million USD | 95.102% |
Aquestive Therapeutics, Inc. | 29.75 Million USD | 89.735% |
Cumberland Pharmaceuticals Inc. | 33.48 Million USD | 90.879% |
SIGA Technologies, Inc. | 122.09 Million USD | 97.498% |
Lifecore Biomedical, Inc. | 41.85 Million USD | 92.702% |
Shineco, Inc. | 882.16 Thousand USD | -246.212% |
Phibro Animal Health Corporation | 312.48 Million USD | 99.023% |
Procaps Group S.A. | 239.56 Million USD | 98.725% |
TherapeuticsMD, Inc. | 1.3 Million USD | -134.575% |
Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 509.633% |
Viatris Inc. | 6.43 Billion USD | 99.953% |
Sunshine Biopharma, Inc. | 8.33 Million USD | 63.376% |
Rockwell Medical, Inc. | 8.7 Million USD | 64.911% |
Incannex Healthcare Limited | 12 Thousand USD | -25351.442% |
Aytu BioPharma, Inc. | 54.58 Million USD | 94.405% |
Tilray Brands, Inc. | 223.35 Million USD | 98.633% |
Collegium Pharmaceutical, Inc. | 326.16 Million USD | 99.064% |
PetIQ, Inc. | 252.74 Million USD | 98.792% |
Silver Spike Investment Corp. | 8.1 Million USD | 62.306% |
Neurocrine Biosciences, Inc. | 1.84 Billion USD | 99.835% |
Journey Medical Corporation | 52.52 Million USD | 94.185% |
Alimera Sciences, Inc. | 61.17 Million USD | 95.007% |
Petros Pharmaceuticals, Inc. | 4.19 Million USD | 27.128% |
Assertio Holdings, Inc. | 125.04 Million USD | 97.558% |
Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 44941.771% |
Embecta Corp. | 749.9 Million USD | 99.593% |
Cyclo Therapeutics, Inc. | -2.41 Million USD | 226.72% |
Procaps Group, S.A. | 239.56 Million USD | 98.725% |
PainReform Ltd. | -15 Thousand USD | 20461.153% |
Avadel Pharmaceuticals plc | 27.11 Million USD | 88.737% |
Hempacco Co., Inc. | -1.21 Million USD | 351.2% |
Talphera, Inc. | -4.89 Million USD | 162.394% |
Pacira BioSciences, Inc. | 490.3 Million USD | 99.377% |
Alvotech | -69.42 Million USD | 104.399% |
Lantheus Holdings, Inc. | 709.54 Million USD | 99.57% |
Kamada Ltd. | 52.59 Million USD | 94.193% |
Indivior PLC | 907 Million USD | 99.663% |
Currenc Group, Inc. | 17.35 Million USD | 82.403% |
Evoke Pharma, Inc. | 4.97 Million USD | 38.656% |
Flora Growth Corp. | 17.73 Million USD | 82.782% |
Cyclo Therapeutics, Inc. | -2.41 Million USD | 226.72% |
Evolus, Inc. | 140.52 Million USD | 97.827% |
HUTCHMED (China) Limited | 453.55 Million USD | 99.327% |
Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 99.112% |
Akanda Corp. | 111.44 Thousand USD | -2640.422% |